ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to characterize the safety and efficacy of AMXI-5001.
Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency, Prostate Cancer, Pancreatic Cancer
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to characterize the safety and efficacy of AMXI-5001.
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
-
University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles, California, United States, 90404
Moffitt Cancer Center and Research Institute, Tampa, Florida, United States, 33612
Johns Hopkins, Baltimore, Maryland, United States, 21218
SCRI Oncology Partners, Nashville, Tennessee, United States, 37203
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, 77030
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
AtlasMedx, Incorporated,
Pamela Munster, MD, STUDY_DIRECTOR, AtlasMedx, Incorporated
2026-10